Chlamydia Infection Diagnostics Market - Forecasts from 2024 to 2029

The chlamydia infection diagnostics market was valued at US$1, 211.526 million in 2022.

Chlamydia diagnostics are tests and procedures used to identify the chlamydia trachomatis bacteria’s presence in an individual. It is a sexually transmitted disease and is asymptomatic, which means the symptoms of chlamydia are not seen but the person can still be infected. Therefore, early diagnosis and treatment of chlamydia disease is important.

Driving factors for the chlamydia infection diagnostics market

The major factor influencing the growth of the chlamydia infection diagnostics market is the rising testing frequency and the increase in demand for quick and reliable testing. Molecular diagnostics have experienced a huge surge in the chlamydia infection diagnostics industry. To meet the rising demand there have been various technological advantages, including quick and point-of-care testing options. Further, various government initiatives are also fueling the chlamydia infection diagnostics market growth. For instance, the National Chlamydia Screening Program (NCSP) by the government of the United Kingdom.

Growing prevalence of sexually transmitted disease

Chlamydia infection has been growing at a rapid pace. This growth is majorly due to changing sexual behaviour and the lack of awareness of STDs essentially chlamydia among individuals. If chlamydia is untreated, it can affect the human body and cause serious health complications. Therefore, the demand for accurate and timely diagnosis is significantly increasing. Additionally, the need for novel diagnostic approaches to treat antibiotic-resistant strains to treat chlamydia bacteria has increased. Owing to this various chlamydia infection diagnostics industry players are focusing on new product development.

Increase in people suffering from chlamydia infection

There has been significant growth in people suffering from chlamydia infection owing to the lack of awareness among individuals and changing sexual behavior. For instance, as per the CDC data published in 2021, 1, 644, 416 cases of chlamydia were reported, making it one of the most prevalent diseases in the United States. This signifies that there were 495.5 cases per 100, 000 people in the United States in 2020. The growing rate of this disease is increasing the diagnosis and treatment with the use of advanced tests and is expected to fuel the chlamydia infection diagnostics market growth.

Rising global agency support

According to the report published by The WHO in the year 2020, the agency plans to reduce the STI prevalence around the globe. Owing to this, the diagnosis and treatment for chlamydia has increased significantly. Furthermore, various councils and colleges have been focusing on promoting the diagnosis and treatment of various STDs especially chlamydia, which has a long-term effect on the female body. If chlamydia is diagnosed at an earlier stage it can be treated easily. Various government initiatives have been taking place to eradicate the cases of chlamydia globally.

Growing popularity of the Nucleic Acid Amplification Test (NAAT)

The Nucleic Acid Amplification Test is a molecular test that detects DNA. To diagnose chlamydia infection NAAT detects chlamydia trachomatis RNA or DNA in biological sample. The NAAT method is more sensitive and specific, and it’s performed on vaginal swabs from women and urine for both males and females. Additionally, in March 2022, the Binx Health IO CT/N assay was approved by the FDA at point-of-care settings in various end users. Product approvals further increase the prominence of NAAT in the chlamydia infection diagnostics market

Development of advanced diagnostic technologies

The development of various advanced diagnostic technologies like molecular diagnostic tests is one of the key factors fueling the chlamydia infection diagnostics market. This has led to the development of various accurate and sensitive chlamydia diagnostic tests. For instance, Roche collaborated with NICE to introduce guidelines for molecular diagnostic usage for the diagnosis of chlamydia. These guidelines have helped diagnostic tests to be standardized in the United Kingdom. The increasing healthcare expenditure globally is leading to various investments, including technologically advanced diagnostic facilities.

Proliferating applications in hospitals

Hospitals are anticipated to hold the maximum chlamydia infection diagnostics market share. The effortless accessibility of infrastructure and qualified physicians are the key growth drivers for this development. There are huge numbers of patients who require diagnosis in hospitals and the easy availability of screening tests in hospitals to detect chlamydia is fueling the chlamydia infection diagnostics market growth. Moreover, diagnostic centers are also anticipated to grow significantly due to the surging application of molecular diagnosis of chlamydia trachomatis including the application of NAAT.

In North America, it is projected that the chlamydia infection diagnostics market will grow steadily.

The North American region is anticipated to secure a sizable chlamydia infection diagnostics market share. The regional chlamydia infection diagnostics industry will be fueled by the increasing prevalence of chlamydia infection and new product innovation by key manufacturers. For instance, according to the CDC, nearly 1.6 million people in the United States were infected with chlamydia in 2021. Furthermore, the increasing product innovation and approvals are surging the growth of the chlamydia infection diagnostics market in the region. In May 2022, Abbott’s Alinity m STI assay received approval from the FDA. Alinity m STI requires one swab sample or urine sample to diagnose chlamydia.

Market Key Developments

• In May 2023, The Visby Medical Sexual Health Test, a polymerase chain reaction (PCR) diagnostic test for the identification of sexually transmitted infections (STIs) caused by Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis in women, has been approved by the Food and Drug Administration (FDA).
• In May 2022, BD introduced the BD COR MX instrument which is an automated high-throughput molecular diagnostic platform in the United States.
• In April 2022, the Chiricahua Community Health Centers, Inc. (CCHCI) collaborated with Visby Medical Inc., and The Body Agency Collective to improve STD diagnosis and treatment including chlamydia.

Segmentation:

By Product Type

• Diagnostics
• Therapeutics

By Test Type

• Culture Tests
• Nucleic Acid Amplification Test
• Direct Fluorescent Antibody Test
• Serology Tests
• Others

By End-User

• Hospitals
• Diagnostic Centers
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others